Robert Nelsen is a co-founder and Managing Director of ARCH Venture Partners, where he has participated in the creation. See sector focus and contact routes.
Robert Nelsen is a co-founder and Managing Director of ARCH Venture Partners, where he has participated in the creation, financing, and development of more than 150 companies since the firm’s founding. His investment thesis centers on disruptive technologies and novel platform platforms, with a primary focus on early-stage life sciences ventures originating from universities and national laboratories. Nelsen typically leads early-stage deals, having served as the lead partner on 50 transactions, and concentrates on seed to early-stage rounds that aim for valuations exceeding $1 billion. Notable portfolio companies he has backed include Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, and Beam Therapeutics, many of which have reached billion-dollar valuations or been acquired by major pharmaceutical firms. He emphasizes partnering directly with founding teams to execute visions in biotechnology and novel therapeutic platforms rather than following later-stage trends. While specific check sizes are not publicly detailed in available sources, his track record includes over 50 early-stage investments that achieved valuations above $1 billion, indicating
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Chicago.
Investors like Robert Nelsen · Full investor directory · Investor access · Company funding database